Stenocare Past Earnings Performance
Past criteria checks 0/6
Stenocare's earnings have been declining at an average annual rate of -28%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 13.4% per year.
Key information
-28.0%
Earnings growth rate
-19.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.4% |
| Return on equity | -87.1% |
| Net Margin | -734.7% |
| Next Earnings Update | 27 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Stenocare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -16 | 7 | 0 |
| 30 Jun 24 | 3 | -17 | 6 | 0 |
| 31 Mar 24 | 4 | -17 | 6 | 0 |
| 31 Dec 23 | 4 | -18 | 6 | 0 |
| 30 Sep 23 | 6 | -17 | 7 | 0 |
| 30 Jun 23 | 6 | -16 | 7 | 0 |
| 31 Mar 23 | 4 | -17 | 7 | 0 |
| 31 Dec 22 | 4 | -16 | 7 | 0 |
| 30 Sep 22 | 2 | -18 | 7 | 0 |
| 30 Jun 22 | 1 | -16 | 7 | 0 |
| 31 Mar 22 | 2 | -14 | 7 | 0 |
| 31 Dec 21 | 2 | -13 | 7 | 0 |
| 30 Sep 21 | 2 | -12 | 7 | 0 |
| 30 Jun 21 | 2 | -11 | 7 | 0 |
| 31 Mar 21 | 1 | -12 | 6 | 0 |
| 31 Dec 20 | 0 | -12 | 6 | 0 |
| 30 Sep 20 | 0 | -3 | 5 | 0 |
| 30 Jun 20 | 0 | -4 | 5 | 0 |
| 31 Mar 20 | 1 | -2 | 5 | 0 |
| 31 Dec 19 | 5 | 2 | 4 | 0 |
| 30 Sep 19 | 7 | -4 | 4 | 0 |
| 30 Jun 19 | 8 | -1 | 3 | 0 |
| 31 Mar 19 | 8 | -1 | 3 | 0 |
| 31 Dec 18 | 4 | -3 | 2 | 0 |
Quality Earnings: S7C is currently unprofitable.
Growing Profit Margin: S7C is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: S7C is unprofitable, and losses have increased over the past 5 years at a rate of 28% per year.
Accelerating Growth: Unable to compare S7C's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: S7C is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: S7C has a negative Return on Equity (-87.08%), as it is currently unprofitable.